Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

Denham, James W., Steigler, Allison, Lamb, David S., Joseph, David, Mameghan, Hedy, Turner, Ssndra, Matthews, John, Franklin, Ian, Atkinson, Chris, North, John, Poulsen, Michael, Christie, David, Spry, Nigel A., Tai, Keen-Hun, Wynne, Chris, Duchesne, Gillian, Kovacev, Olga and D'Este, Catherine (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncology, 6 11: 841-850. doi:10.1016/S1470-2045(05)70348-X


Author Denham, James W.
Steigler, Allison
Lamb, David S.
Joseph, David
Mameghan, Hedy
Turner, Ssndra
Matthews, John
Franklin, Ian
Atkinson, Chris
North, John
Poulsen, Michael
Christie, David
Spry, Nigel A.
Tai, Keen-Hun
Wynne, Chris
Duchesne, Gillian
Kovacev, Olga
D'Este, Catherine
Title Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
Journal name Lancet Oncology   Check publisher's open access policy
ISSN 1470-2045
1474-5488
Publication date 2005-11-01
Year available 2005
Sub-type Article (original research)
DOI 10.1016/S1470-2045(05)70348-X
Open Access Status Not yet assessed
Volume 6
Issue 11
Start page 841
End page 850
Total pages 10
Place of publication London, United Kingdom
Publisher The Lancet Publishing Group
Language eng
Abstract Background Androgen deprivation is an established treatment regimen for disseminated prostate cancer; however, its role in patients with localised cancer is less clear. We did a large randomised controlled trial to determine whether 3 months or 6 months of androgen deprivation given before and during radiotherapy improves outcomes for patients with locally advanced prostate cancer.
Formatted abstract
Background: Androgen deprivation is an established treatment regimen for disseminated prostate cancer; however, its role in patients with localised cancer is less clear. We did a large randomised controlled trial to determine whether 3 months or 6 months of androgen deprivation given before and during radiotherapy improves outcomes for patients with locally advanced prostate cancer.
Methods: 818 men with locally advanced prostate cancer were randomly assigned to: no androgen deprivation (ie, radiotherapy alone: 66 Gy in 33 fractions of 2 Gy per day over 6·5–7·0 weeks to the prostate and seminal vesicles); 3 months' androgen deprivation with 3·6 mg goserelin given subcutaneously every month and 250 mg flutamide given orally three times a day starting 2 months before radiotherapy (same regimen as control group); or 6 months' androgen deprivation, with the same regimen, starting 5 months before radiotherapy (same regimen as control group). Primary endpoints were time to local failure and prostate-cancer-specific survival; secondary endpoints were distant failure, disease-free survival, and freedom from salvage treatment. Analyses were done by intention to treat.
Findings: 802 (98%) patients were eligible for analysis. Median follow-up was 5·9 years (range 0·1–8·5). Compared with patients assigned no androgen deprivation, those assigned 3 months' treatment had significantly improved local failure (hazard ratio [HR] 0·56 [95% CI 0·39–0·79], p=0·001), biochemical failure-free survival (0·70 [0·56–0·88], p=0·002), disease-free survival (0·65 [0·52–0·80], p=0·0001), and freedom from salvage treatment (0·73 [0·56–0·96], p=0·025). 6 months' androgen deprivation significantly improved local failure (0·42 [0·28–0·62], p<0·0001), biochemical failure-free survival (0·58 [0·46–0·74], p<0·0001), disease-free survival (0·56 [0·45–0·69], p<0·0001), freedom from salvage treatment (0·53 [0·40–0·71], p<0·0001), distant failure (0·67 [0·45–0·99], p=0·046) and prostate-cancer-specific survival (0·56 [0·32–0·98], p=0·04) compared with no androgen deprivation.
Interpretation: 6 months' androgen deprivation given before and during radiotherapy improves the outlook of patients with locally advanced prostate cancer. Further follow-up is needed to estimate precisely the size of survival benefits. Increased radiation doses and additional periods of androgen deprivation might lead to further benefit.
Keyword Oncology
Oncology
ONCOLOGY
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 286 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 313 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 24 Nov 2010, 00:46:04 EST